SANUWAVE Health
SANUWAVE Health's revenue rose 35.0% to $44 million in fiscal 2025. Its operating margin was 11.2%, down from 11.8% a year earlier. Free cash flow was $2 million, down 1.6%. The diluted share count rose 103.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1 | 1 | 2 | 10 | 12 |
| Debt incl. finance leases | 26 | — | — | — | 22 |
| Net debt (negative means net cash) | 26 | — | — | — | 10 |
| Net debt to EBITDA | — | — | — | — | 1.7x |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −2.0x | −0.7x | −0.3x | 0.3x | 1.3x |
| Current ratio | 0.1x | 0.1x | 0.1x | 0.4x | 1.4x |
| Quick ratio | 0.1x | 0.1x | 0.1x | 0.3x | 1.1x |
Cash flow
Projections
Project SANUWAVE Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought SANUWAVE Health shares on the open market, and 3 insiders sold $7.2 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 1, 2026 | Opaleye Management Inc.10% owner | Sold | 10,581 | $16.11 | $170,460 | Form 4 |
| Apr 30, 2026 | Opaleye Management Inc.10% owner | Sold | 25,000 | $16.15 | $403,750 | Form 4 |
| Apr 29, 2026 | Opaleye Management Inc.10% owner | Sold | 24,360 | $17.25 | $420,210 | Form 4 |
| Apr 28, 2026 | Opaleye Management Inc.10% owner | Sold | 46,288 | $18.47 | $854,939 | Form 4 |
| Apr 21, 2026 | Opaleye Management Inc.10% owner | Sold | 202 | $20.50 | $4,141 | Form 4 |
| Apr 17, 2026 | Opaleye Management Inc.10% owner | Sold | 16,267 | $20.46 | $332,823 | Form 4 |
| Dec 12, 2025 | Manchester Management Pr LlcDirector by Deputization | Sold | 6,500 | $21.04 | $136,760 | Form 4 |
| Dec 11, 2025 | Manchester Management Pr LlcDirector by Deputization | Sold | 13,500 | $31.28 | $422,280 | Form 4 |
| Dec 10, 2025 | Manchester Management Co LlcDirector by Deputization | Sold | 8,625 | $30.39 | $262,114 | Form 4 |
| Dec 9, 2025 | Manchester Management Co LlcDirector by Deputization | Sold | 8,785 | $30.58 | $268,645 | Form 4 |
| Dec 8, 2025 | Manchester Management Co LlcDirector by Deputization | Sold | 127,400 | $30.76 | $3.9 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −0.4% | 66.0% | 39.4% |
| Altman Z'' | −48.96 | −32.94 | −19.06 |
| Accruals ratio | −100.6% | −135.3% | 23.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put SANUWAVE Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| SANUWAVE Health | FY25 | 35.0% | 11.2% | 4.4% | — | 1.7x | — | |
| TriSalus Life Sciences | FY25 | 53.4% | −59.7% | −41.9% | — | — | 3 | Compare |
| SS Innovations International | FY25 | 105.7% | −19.3% | −52.3% | — | — | — | Compare |
| Shoulder Innovations | FY25 | 49.6% | −55.6% | −76.1% | — | — | — | Compare |
| KORU Medical Systems | FY25 | 22.2% | −7.2% | −1.1% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1 | 1 | 2 | 2 | 4 | 13 | 17 | 20 | 33 | 44 |
| Revenue growth | 42.5% | −46.3% | 150.5% | −17.4% | 165.4% | 220.7% | 28.7% | 21.8% | 60.0% | 35.0% |
| Gross profit | 1 | 0 | 1 | 0 | 3 | 8 | 12 | 14 | 24 | 34 |
| Research and development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | −3 | −4 | −7 | −9 | −25 | −14 | −9 | −0 | 4 | 5 |
| Net income | −6 | −6 | −12 | −10 | −31 | −27 | −10 | −26 | −33 | 12 |
| Diluted EPS (US$) | −0.06 | −0.04 | −0.08 | −0.05 | −0.08 | −0.05 | −0.02 | −12.19 | −7.41 | 0.41 |
| Diluted shares (millions) | 108 | 139 | 150 | 204 | 378 | 518 | 550 | 2 | 4 | 9 |
| Cash flow | ||||||||||
| Cash from operations | −3 | −2 | −4 | −6 | −13 | −6 | −17 | −4 | 2 | 4 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 | 2 |
| Free cash flow | −3 | −2 | −4 | −6 | −13 | −7 | — | −5 | 2 | 2 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 2 | 0 | 0 | 0 | — | 0 | 2 | 5 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 0 | 1 | 0 | 2 | 2 | 1 | 1 | 2 | 10 | 12 |
| Debt incl. finance leases | 5 | — | — | — | 17 | 26 | — | — | — | 22 |
| Total assets | 1 | 1 | 1 | 3 | 23 | 19 | 20 | 22 | 30 | 37 |
| Total liabilities | 8 | 11 | 16 | 13 | 37 | 58 | 61 | 66 | 46 | 36 |
| Shareholders' equity | −7 | −10 | −15 | −10 | −14 | −39 | −41 | −44 | −16 | 2 |
| Margins and ratios | ||||||||||
| Gross margin | 58.9% | 67.2% | 62.5% | 32.0% | 71.4% | 61.7% | 74.1% | 70.4% | 75.2% | 77.1% |
| Operating margin | −241.0% | −517.9% | −388.1% | −575.3% | −621.1% | −108.7% | −53.5% | −2.6% | 11.8% | 11.2% |
| Net margin | −467.9% | −749.9% | −628.7% | −682.3% | −762.6% | −209.5% | −61.5% | −126.5% | −101.4% | 26.8% |
| Free cash flow margin | −233.3% | −207.0% | −198.1% | −422.9% | −314.8% | −53.3% | — | −22.2% | 6.0% | 4.4% |
| Rule of 40 (growth + FCF margin) | −190.7% | −253.4% | −47.5% | −440.2% | −149.4% | 167.3% | — | −0.4% | 66.0% | 39.4% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | — | — | — | — | — | — |
| Return on assets | −656.0% | −485.0% | −947.0% | −457.5% | −234.3% | −130.9% | −53.5% | −122.0% | −126.0% | 35.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | 1.7x |